APA

Trancart S., Charreau I., Marchou B., Bocquentin M., Molina J., Izopet J., Tangre P., Aboulker J. & Taburet A. (20120824). Presence of lamivudine or emtricitabine is associated with reduced emergence of nonnucleoside reverse transcriptase inhibitor mutations in an efavirenz-based intermittent antiretroviral treatment regimen. : Antimicrobial agents and chemotherapy.

Chicago

Trancart Stéphanie, Charreau Isabelle, Marchou Bruno, Bocquentin Muriel, Molina Jean-Michel, Izopet Jacques, Tangre Philippe, Aboulker Jean-Pierre and Taburet Anne-Marie. 20120824. Presence of lamivudine or emtricitabine is associated with reduced emergence of nonnucleoside reverse transcriptase inhibitor mutations in an efavirenz-based intermittent antiretroviral treatment regimen. : Antimicrobial agents and chemotherapy.

Harvard

Trancart S., Charreau I., Marchou B., Bocquentin M., Molina J., Izopet J., Tangre P., Aboulker J. and Taburet A. (20120824). Presence of lamivudine or emtricitabine is associated with reduced emergence of nonnucleoside reverse transcriptase inhibitor mutations in an efavirenz-based intermittent antiretroviral treatment regimen. : Antimicrobial agents and chemotherapy.

MLA

Trancart Stéphanie, Charreau Isabelle, Marchou Bruno, Bocquentin Muriel, Molina Jean-Michel, Izopet Jacques, Tangre Philippe, Aboulker Jean-Pierre and Taburet Anne-Marie. Presence of lamivudine or emtricitabine is associated with reduced emergence of nonnucleoside reverse transcriptase inhibitor mutations in an efavirenz-based intermittent antiretroviral treatment regimen. : Antimicrobial agents and chemotherapy. 20120824.